A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD.
The DOI matches its Crossref record, with a small difference in title or year; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Hallucinogen persisting perception disorder (HPPD) is rarely encountered in clinical settings. It is described as a re-experiencing of some perceptual distortions induced while intoxicated and suggested to subsequently cause functional impairment or anxiety. Two forms exist: Type 1, which are brief "flashbacks," and Type 2 claimed to be chronic, waxing, and waning over months to years. A review of HPPD is presented. In addition, data from a comprehensive survey of 20 subjects reporting Type-2 HPPD-like symptoms are presented and evaluated. Dissociative Symptoms are consistently associated with HPPD. Results of the survey suggest that HPPD is in most cases due to a subtle over-activation of predominantly neural visual pathways that worsens anxiety after ingestion of arousal-altering drugs, including non-hallucinogenic substances. Individual or family histories of anxiety and pre-drug use complaints of tinnitus, eye floaters, and concentration problems may predict vulnerability for HPPD. Future research should take a broader outlook as many perceptual symptoms reported were not first experienced while intoxicated and are partially associated with pre-existing psychiatric comorbidity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Development, reliability, and validity of a dissociation scale
BERNSTEIN, E. M., & PUTNAM, F. W. (1986) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198612000-00004 · Cited by 3,793
(2017) · Institute for Social Research eBooks · doi:10.3998/2027.42/139710 · Cited by 1,364
(1993) · Cited by 1,279
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532
ADVERSE REACTIONS TO PSYCHEDELIC DRUGS. A REVIEW OF THE LITERATURE
Strassman, R. J. (1984) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198410000-00001 · Cited by 312
LYSERGIC ACID DIETHYLAMIDE: SIDE EFFECTS AND COMPLICATIONS
COHEN, S. (1960) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196001000-00005 · Cited by 287
Hallucinogen persisting perception disorder: what do we know after 50 years?
Halpern, J. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00306-x · Cited by 219
Self-citationThe Psychopharmacology of Hallucinogens
Abraham, H., Aldridge, A. M., & Gogia, P. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00136-2 · Cited by 172
Research works printed but not linked: 6
- Fischer R (1976) On the remembrance of things present: the state-bound and stage-bound nature of consciousness. Man-Environ Syst 6:131–136
- Grinspoon L, Bakalar J (1997) Psychedelics reconsidered, 3rd edn. The Lindesmith Center, New York
- Parish E (1894) Über die Trugwahrnehmungen mit besonderer Berücksichtigung der internationalen Enquete über Wachhalluzinationen bei Gesunden. Schr Ges psychol Forsch 7(8):1–154
- Passie T, Halpern JH (2014) The pharmacology of hallucinogens (Chapter 14). In: Ries RK, Fiellin DA (eds) Principles of addiction medicine, 5th edn. Lippincott Williams & Wilkins, NY
- Substance Abuse and Mental Health Services Administration (SAMHSA) (2011) Results from the 2010 national survey on drug use and health: summary of national findings. Substance Abuse and Mental Health Services Administration, Rockville
- World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders. World Health Organization, Geneva
Cited by
REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
“Its prevalence appears to be low and its etiology complex, but symptoms can still be distressing for individuals (Halpern et al., 2018).”
BackgroundAdverse effects of psychedelics: From anecdotes and misinformation to systematic science
Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069100 · Cited by 325
“Although Halpern and Pope (2003) suggest that there may be no identifiable risk factors for HPPD, a subsequent study of 19 individuals who developed HPPD found that all recalled anxiety and/or panic reactions during the triggering episode (Halpern et al., 2016).”
BackgroundTowards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313
“Along these lines, most people who develop HPPD report that distressing symptoms appeared after a frightening acute psychedelic experience [163].”
BackgroundLong-term effects of psychedelic drugs: A systematic review
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.03.017 · Cited by 257
Modern clinical research on LSD
Liechti, M. E. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.86 · Cited by 236
“However, the prevalence and relevance of HPPD is unclear and needs to be studied (Halpern et al, 2016).”
BackgroundLong-lasting subjective effects of LSD in normal subjects.
Schmid, Y., & Liechti, M. E. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4733-3 · Cited by 232
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Extended difficulties following the use of psychedelic drugs: A mixed methods study
Evans, J., Robinson, O. C., Argyri, E. K., Suseelan, S., Murphy-Beiner, A., McAlpine, R., Luke, D., Michelle, K., & Prideaux, E. (2023) · PLOS ONE · doi:10.1371/journal.pone.0293349 · Cited by 185
Breeksema, J. J., Kuin, B. W., Kamphuis, J., van den Brink, W., Vermetten, E., & Schoevers, R. A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221116926 · Cited by 178
“Flashbacks were later included in the diagnostic category “hallucinogen persisting perception disorder” (HPPD, which appears in the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) but not in the International Statistical Classification of Diseases and Related Health Problems (ICD10); HPPD is reported occ…”
BackgroundMartinotti, G., Santacroce, R., Pettorruso, M., Montemitro, C., Spano, M., Lorusso, M., Di Giannantonio, M., & Lerner, A. (2018) · Brain Sciences · doi:10.3390/brainsci8030047 · Cited by 171
“Nonetheless, HPPD-like experiences, such as flashbacks, moments of derealization, and hyper-intense perceptions are reported in healthy populations and non-LSD exposed subjects [40].”
BackgroundInfluentialSelf-citationShalit, N., Rehm, J., & Lev-Ran, S. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.09.020 · Cited by 129
Visual snow syndrome: A clinical and phenotypical description of 1,100 cases
Puledda, F., Schankin, C. J., & Goadsby, P. J. (2020) · Neurology · doi:10.1212/wnl.0000000000008909 · Cited by 124
“Migraine aura 127/345 (37) 1/6 (17) 1/10 (10) 21 (27)”
Behavioral Neurobiology of Psychedelic Drugs
(2018) · Current topics in behavioral neurosciences · doi:10.1007/978-3-662-55880-5 · Cited by 118
Orsolini, L., Papanti, G. D., De Berardis, D., Guirguis, A., Corkery, J. M., & Schifano, F. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00240 · Cited by 99
Bender, D., & Hellerstein, D. J. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06049-6 · Cited by 88
“Classical psychedelics have been characterized as “meaning-response magnifiers” or “amplifiers of consciousness” (Hartogsohn 2016).”
BackgroundA narrative synthesis of research with 5-MeO-DMT
Ermakova, A. O., Dunbar, F., Rucker, J., & Johnson, M. W. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211050543 · Cited by 86
“…of people reporting symptoms of HPPD found that symptoms were more frequently preceded by use of non-psychedelic substances such as alcohol, tobacco and cannabis than by the use of psychedelics and that some individuals with these symptoms had never taken a psychedelic (Halpern et al., 2018).”
BackgroundPsychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
Insular and occipital changes in visual snow syndrome: a BOLD fMRI and MRS study
Puledda, F., Ffytche, D. H., Lythgoe, D. J., O’Daly, O., Schankin, C. J., Williams, S., & Goadsby, P. J. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50986 · Cited by 67
Disrupted connectivity within visual, attentional and salience networks in the visual snow syndrome
Puledda, F., O’Daly, O., Schankin, C. J., Ffytche, D. H., Williams, S., & Goadsby, P. J. (2021) · Human Brain Mapping · doi:10.1002/hbm.25343 · Cited by 65
Safety pharmacology of acute LSD administration in healthy subjects
Holze, F., Caluori, T. V., Vizeli, P., & Liechti, M. E. (2022) · Psychopharmacology · doi:10.1007/s00213-021-05978-6 · Cited by 61
Müller, F., Kraus, E., Holze, F., Becker, A., Ley, L., Schmid, Y., Vizeli, P., Liechti, M. E., & Borgwardt, S. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06066-z · Cited by 61
The Emerging Field of Psychedelic Psychotherapy
Barber, G., & Aaronson, S. T. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01363-y · Cited by 68
Psychedelic drugs and perception: a narrative review of the first era of research
Aday, J. S., Wood, J. R., Bloesch, E. K., & Davoli, C. C. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0094 · Cited by 57
“Doing so can strengthen our understanding of the perceptual effects of psychedelics, whichmay be relevant for clinical conditions such as hallucinogen persisting perception disorder (HPPD; Halpern et al. 2016).”
BackgroundBorkel, L. F., Rojas‐Hernández, J., Henríquez‐Hernández, L. A., Santana, Á., & Hernández, D. J. Q. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2295997 · Cited by 57
On Perception and Consciousness in HPPD: A Systematic Review
Vis, P. J., Goudriaan, A. E., ter Meulen, B. C., & Blom, J. D. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.675768 · Cited by 46
“They are primarily associated with the prior use of lysergic acid diethylamide (LSD), but other known triggers include alcohol, cannabis, ketamine, 3,4-methylenedioxymethamphetamine (MDMA), psilocybin, and synthetic cannabinoids (Abraham, 1983; Litjens et al., 2014; Lerner et al., 2014a; Orsolini et al., 2017; Halpern…”
BackgroundPsychedelics for treatment resistant depression: are they game changers?
Kalfas, M., Taylor, R. H., Tsapekos, D., & Young, A. H. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2281582 · Cited by 40
“HPPD may be partially associated with preexisting psychiatric comorbidity, such as individual or family history of anxiety [127].”
BackgroundPsychedelic use and psychiatric risks
Simonsson, O., Goldberg, S. B., Chambers, R., Osika, W., Simonsson, C., & Hendricks, P. S. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06478-5 · Cited by 41
“Given that the estimated prevalence rate of HPPD type II among hallucinogen users is extremely low (Halpern et al. 2016), it is possible that those respondents who reported HPPD diagnosis by a doctor or other medical professional had received a HPPD type I diagnosis.”
van Dongen, R. M., Alderliefste, G. J., Onderwater, G. L. J., Ferrari, M. D., & Terwindt, G. M. (2021) · European Journal of Neurology · doi:10.1111/ene.14914 · Cited by 32
““Type 2 HPPD” has been the proposed term for the latter [12].”
BackgroundWięckiewicz, G., Stokłosa, I., Piegza, M. J., Gorczyca, P. W., & Pudło, R. (2021) · Pharmaceuticals · doi:10.3390/ph14080793 · Cited by 32
“Since the etiology and scientifically proven treatments remain unknown, HPPD should be considered a significant risk for patients undergoing treatment with psychedelics, according to the authors [37].”
BackgroundHallucinogenic persisting perception disorder: a case series and review of the literature.
Ford, H., Fraser, C. L., Solly, E., Clough, M., Fielding, J., White, O., & Van Der Walt, A. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.878609 · Cited by 28
“The overlap of HPPDwith drug-induced psychosis and other differential diagnoses such as migraine aura without headache, focal epilepsies, visual snow syndrome (VSS) and narcolepsy-cataplexy syndrome further complicates the epidemiology (13, 15, 16).”
BackgroundSafety pharmacology of acute psilocybin administration in healthy participants
Straumann, I., Holze, F., Becker, A., Ley, L., Halter, N., & Liechti, M. E. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104060 · Cited by 31
“Hallucinogen persisting perception disorder (Halpern et al., 2016) was not observed in the present pooled analysis.”
Psychedelic experiences and long-term spiritual growth: a systematic review
Schutt, W. A., Exline, J. J., Pait, K. C., & Wilt, J. A. (2024) · Current Psychology · doi:10.1007/s12144-024-06272-2 · Cited by 32
“…et al., 2016; Carbonaro et al., 2016, Johnstad, 2021), persisting changes in perception or mood (e.g., Hallucinogen Persisting Perception Disorder; Halpern et al., 2018 ), adverse neurological side effects (see Parrott, 2014a, b), and legal problems in areas where the substances are illegal…”
Calder, A. E., & Hasler, G. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.091 · Cited by 28
Irvine, A., & Luke, D. P. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00195 · Cited by 25
Bernal, A. M. O., Raison, C. L., Lancelotta, R., & Davis, A. K. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1049643 · Cited by 35
“Mixed methods research designs that can collect qualitative data regarding reactivation details in upcoming clinical trials will be very valuable to enhance our understanding of the reactivation phenomena and how it may compare to HPPD Type 1 and 2.”
BackgroundMethodResultInfluentialHallucinogen persisting perception disorder: A literature review and three case reports
Skryabin, V. Y., Vinnikova, M., Nenastieva, A., & Alekseyuk, V. (2018) · Journal of Addictive Diseases · doi:10.1080/10550887.2019.1673655 · Cited by 25
“The pharmacotherapy of HPPD may be different from study to study, and any recommendations are based almost entirely on non-controlled studies of small patient populations or single case reports.14,15 Some patients show benefit from various SSRIs, low-dose olanzapine, quetiapine, amisulpride, aripiprazole and asenapine…”
BackgroundInfluentialPsychological effects of psychedelics in adolescents
Izmi, N., Carhart-Harris, R. L., & Kettner, H. (2024) · Frontiers in Child and Adolescent Psychiatry · doi:10.3389/frcha.2024.1364617 · Cited by 31
Greń, J., Tylš, F., Lasocik, M., & Kiraly, C. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1054692 · Cited by 34
Kruger, D. J., Aday, J. S., Fields, C. W., Kolbman, N., Glynos, N. G., Barron, J., Herberholz, M., & Boehnke, K. F. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2024.0011 · Cited by 28
“23,24 Some hypothesize that HPPD may be a form of anxiety 4 or traumatic anxiety disorder similar to PTSD. 25 As psychedelics can induce a state of suggestibility and increased vulnerability, 26 there is also an emerging discussion in the fi eld regarding the potential for therapist abuse and sexual…”
Visual Snow: Updates on Pathology
Fraser, C. L. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01182-x · Cited by 30
Illusions, hallucinations, and visual snow
Fraser, C. L., & Lueck, C. J. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-821377-3.00014-3 · Cited by 25
Not All Cases of Visual Snows are Benign: Mimics of Visual Snow Syndrome
Hang, C., Leishangthem, L., & Yan, Y. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s338111 · Cited by 22
“002% of hallucinogen users, patients could have symptoms of VS, palinopsia, halos, and after-images.(33) Eren et al reported that a 31-year-old female with episodic migraine showed symptoms of VS after taking 20 mg citalopram for two weeks, and the VS symptoms persisted after stopping the drug.”
BackgroundWolfgang, A. S., & Hoge, C. W. (2023) · Current Psychiatry Reports · doi:10.1007/s11920-023-01446-4 · Cited by 25
“HPPD is extremely rare, with 1 in 50,000 recreational users reporting chronic HPPD symptoms [80].”
BackgroundSubstance-Related and Addictive Disorders
(2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890425787.x16_substance_related_disorders · Cited by 25
Gomez-Escolar, A., Folch‐Sanchez, D., Stefaniuk, J., Swithenbank, Z., Nisa, A., Braddick, F., Chaudhary, N. I., van der Meer, P. B., & Batalla, A. (2024) · CNS Drugs · doi:10.1007/s40263-024-01101-3 · Cited by 22
“The term refers to re-experiencing one or more of the perceptual effects induced by a hallucinogen at a later time, after the acute drug effects wear off [109].”
Basedow, L. A., Riemer, T., Reiche, S., Kreutz, R. H., & Majić, T. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.739966 · Cited by 20
“Reports of HPPD are rare andmost commonly related to the use of LSD, with only one case so far involving psilocybin and no reported cases involving ayahuasca or mescaline (Martinotti et al., 2018).”
BackgroundInfluentialPsychedelic science in post-COVID-19 psychiatry
Kelly, J. R., Crockett, M. T., Alexander, L., Haran, M., Baker, A., Burke, L., Brennan, C., & O’Keane, V. (2021) · Irish Journal of Psychological Medicine · doi:10.1017/ipm.2020.94 · Cited by 16
“A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. Current Topics in Behavioral Neurosciences 36, 333–360.”
BackgroundInfluentialPouyan, N., Khankahdani, Z. H., Sisi, F. Y., Lee, Y. L., Rosenblat, J. D., Teopiz, K. M., Lui, L. M. W., Subramaniapillai, M., Lin, K., Nasri, F., et al. (2022) · CNS Drugs · doi:10.1007/s40263-022-00944-y · Cited by 18
“The forgoing cognitive alterations, similar to other acute effects, are reported to fade after the peak psychedelics experience, while some reports suggest enduring and lasting perception problems as side effects [125].”
Ledwos, N., Rosenblat, J. D., Blumberger, D. M., Castle, D. J., McIntyre, R. S., Mulsant, B. H., & Husain, M. I. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001608 · Cited by 20
Schifano, F., Napoletano, F., Chiappini, S., Orsolini, L., Guirguis, A., Corkery, J., Bonaccorso, S., Ricciardi, A., Scherbaum, N., & Vento, A. E. (2019) · Current Addiction Reports · doi:10.1007/s40429-019-00249-z · Cited by 20
Armstrong, S. B., Levin, A. W., Xin, Y., Horan, J., Luoma, J. B., Nagib, P. B., Pilecki, B. C., & Davis, A. K. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00245 · Cited by 20
Elfrink, S., & Bergin, L. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1528253 · Cited by 20
5-Methoxy-N,N-dimethyltryptamine: An Ego-Dissolving Endogenous Neurochemical Catalyst of Creativity
Germann, C. B. (2019) · Activitas Nervosa Superior · doi:10.1007/s41470-019-00063-y · Cited by 16
Bellman, V., Chinthalapally, A., Johnston, E., Russell, N., Bruce, J. M., & Saleem, S. (2022) · Psychiatry Journal · doi:10.1155/2022/3884317 · Cited by 12
Primum non nocere: The onus to characterize the potential harms of psychedelic treatment
Ghaznavi, S., Ruskin, J. N., Haggerty, S. J., King, F., & Rosenbaum, J. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230914 · Cited by 12
Zhou, K., de Wied, D., Carhart-Harris, R. L., & Kettner, H. (2025) · PNAS Nexus · doi:10.1093/pnasnexus/pgae560 · Cited by 24
“The second type, HPPD type 2 or chronic HPPD, is differentiated from flashbacks based on the persisting nature of its symptoms (35).”
InfluentialPsilocybin in pharmacotherapy of obsessive-compulsive disorder
Owe-Larsson, M., Kamińska, K., Buchalska, B., Mirowska-Guzel, D. M., & Cudnoch‐Jędrzejewska, A. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00633-1 · Cited by 15
“Two forms of this perceptual disorder, chronic and short (flashbacks) are known; they may last from weeks, months, years, or even up to a lifetime [144, 145 ].”
BackgroundAnthony, J., WINSTOCK, A. R., Ferris, J., & Nutt, D. (2020) · Drug Science Policy and Law · doi:10.1177/2050324520942345 · Cited by 11
Extended Difficulties Following the Use of Psychedelic Drugs: A Mixed Methods StudyPreprint
Evans, J., Robinson, O. C., Argyri, E. K., Suseelan, S., Murphy-Beiner, A., & McAlpine, R. G. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4487243 · Cited by 12
The Psychedelic Renaissance and Its Forensic Implications.
Holoyda, B. J. (2020) · PubMed · doi:10.29158/jaapl.003917-20 · Cited by 13
Substance-induced psychosis and schizophrenia: the interaction point
Fedotov, I. A., Quattrone, D., & Shustov, D. I. (2020) · I P Pavlov Russian Medical Biological Herald · doi:10.23888/pavlovj2020284593-604 · Cited by 10
Microbiome: The Next Frontier in Psychedelic Renaissance
Kargbo, R. B. (2023) · Journal of Xenobiotics · doi:10.3390/jox13030025 · Cited by 11
Simonsson, O., Hendricks, P. S., Stenfors, C. U. D., Goldberg, S. B., Honk, L., & Osika, W. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231218931 · Cited by 9
“…for hallucinogen persisting perception disorder (HPPD) if they persist and cause significant distress or impairment in daily functioning and other medical or psychiatric conditions can be ruled out (American Psychiatric Association, 2013; see Halpern et al., 2018 for proposed HPPD subtypes).”
BackgroundInfluentialSchetz, D., Schetz, A., & Kocić, I. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112295 · Cited by 9
Turkia, M. (2022) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2022.100029 · Cited by 18
Zhou, K., Wied, D. D., Carhart-Harris, R. L., & Kettner, H. (2022) · doi:10.31234/osf.io/txzha · Cited by 8
Pathological Delta Oscillations in Hallucinogen Persisting Perception Disorder: A Case Report
Haslacher, D., Novkovic, N., Buthut, M., Heinz, A., & Soekadar, S. R. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.867314 · Cited by 7
“Commonly, two types of HPPD were described, an intermittent form characterized by spontaneous and brief recurrence of perceptual distortions or images (Type 1), and a permanent form where patients experience ongoing changes that can fluctuate in their intensity (Type 2) (4, 5).”
BackgroundPsychedelics and psychoanalysis: The journey from talking cure to transformation
Lichtenstein, J., & Hoeh, N. R. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00373 · Cited by 9
Psychedelic-Associated Depersonalization-Derealization Disorder
Michal, M. (2025) · Current topics in behavioral neurosciences · doi:10.1007/7854_2025_599 · Cited by 8
Forstmann, M., & Sagioglou, C. (2021) · European Psychologist · doi:10.1027/1016-9040/a000447 · Cited by 9
Effets psychoactifs des « legal high » : à propos de l’acide lysergique amide (LSA)
Ponté, C., & Lapeyre‐Mestre, M. (2017) · Therapies · doi:10.1016/j.therap.2017.01.012 · Cited by 6
Nutting, S., Bruinsma, T. J., Anderson, M. R., & Jolly, T. S. (2020) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-020-00338-5 · Cited by 6
“Type 2 HPPD is more reflective of DSM-5’s definition of HPPD, whereas type 1 HPPD is more akin to the ICD-10’s flashback definition of HPPD (Orsolini et al. 2017; Martinotti et al. 2018; Halpern et al. 2018).”
BackgroundEvaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective
Marazziti, D., Weiss, F., Gurrieri, R., Russomanno, G., Gambini, M., Magnesa, A., Coccoglioniti, A., & Perugi, G. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2445016 · Cited by 5
“…participants had experienced anxiety and/or panic during the triggering episode, suggesting that HPPD might be interpreted as a form of pathological psychotraumatic response induced by hallucinogenic experiences, with a certain phenomenological overlap with post-traumatic stress disorders [125].”
Persistent Altered States: Psychological Treatment of Psychedelic Adverse Effects
Holmøy, B., & Andersen, K. A. A. (2025) · Tidsskrift for Norsk psykologforening · doi:10.52734/hgsn7664 · Cited by 4
Psychedelic therapeutics in psychiatric conditions
Harvey, P. D., & Nemeroff, C. B. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02335-z · Cited by 8
How do I recognise and manage visual snow syndrome?
Fraser, C. L. (2024) · Eye · doi:10.1038/s41433-024-03059-4 · Cited by 4
“Delayed visual symptoms have also been reported following cannabis, often triggered by subsequent ethanol consumption or anaesthesia [20].”
BackgroundUnderstanding the effects of lysergic acid diethylamide and the importance of its prevention
Okumuş, B., Metin, A., & Kariper, İ. A. (2023) · Health Sciences Review · doi:10.1016/j.hsr.2023.100107 · Cited by 6
Leistenschneider, G., Majić, T., Reiche, S., & Riemer, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-82216-x · Cited by 7
McConnell, A., He, W., McConnell, H. W., Sperandei, S., & Sowman, P. F. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00408 · Cited by 4
Use characteristics and harm potential of ecstasy in The Netherlands
van Amsterdam, J., Ramaekers, J. G., Nabben, T., & van den Brink, W. (2020) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2020.1818692 · Cited by 5
Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review
Neven, A., & Blom, J. D. (2025) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000439 · Cited by 4
“12,13 Type 1 is characterized by reperceptions or flashbacks that arise weeks to months after the intoxication phase and have a duration of seconds to minutes.”
Butler, M., Moore, E., Rucker, J., Lynch-Kelly, K., Hafeez, D., Prideaux, E., Nicholson, T. R., Edwards, M. J., & Pollak, T. A. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04042-1 · Cited by 3
“Some of the visual phenomena reported by people with HPPD, such as transient fl oaters and fl ashes (known as entoptic phenomena) are also reported in healthy populations [22].”
Christian Responses to Psilocybin-Assisted Therapy and Potential Religious and Spiritual Experiences
Macallan, B. C. (2023) · Religions · doi:10.3390/rel14101312 · Cited by 4
Bender, D. A., & Siegel, J. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00043-9 · Cited by 4
Lima, G., Soares, C., Teixeira, M., & Castelo-Branco, M. S. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16264 · Cited by 3
“53 The drugs most related to HPPD are LSD, MDMA, psylocibin and cannabis.”
Classic psychedelics: past uses, present trends, future possibilitiesPreprint
Safron, A., & Johnson, M. W. (2022) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/eys2j · Cited by 6
Psychedelics and the Serotonin Hypothesis of Eating Disorders
Bilenker, D., & Avena, N. M. (2025) · Brain Sciences · doi:10.3390/brainsci15080893 · Cited by 2
“…with psychedelics is Hallucinogen Persisting Perception Disorder (HPPD), a transient visual disturbance including afterimages or visual snow; Type II HPPD, which involves persistent visual disturbances that can interfere with daily life, occurs with an estimated incidence of ~1 in 50,000 [109].”
Bernal, A. M. O., Raison, C. L., Lancelotta, R., Timmermann, C., Sepeda, N. D., & Davis, A. K. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2577305 · Cited by 1
Thakur, D., Dubey, N. P., Singh, R., & Kumar, A. (2025) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2025.2578622 · Cited by 2
Managing Psychological Challenges in the Subacute (“Afterglow”) Window of Psychedelic Drug Effects
Evens, R., Uyar, A., & Majić, T. (2025) · Current topics in behavioral neurosciences · doi:10.1007/7854_2025_612 · Cited by 3
Persistent Tinnitus after Inhaled N,N-dimethyltryptamine (DMT)
Diab, H., & Malcolm, B. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1847366 · Cited by 4
Les psychédéliques, nouvelles perspectives pour les thérapies du traumatisme
Josse, É., Baliko, C., & Dubus, Z. (2023) · HEGEL - HEpato-GastroEntérologie Libérale · doi:10.3917/heg.131.0002 · Cited by 5
Disorders due to Substance Use: Hallucinogens and MDMA-Related Substances
Nayak, S. M., & Johnson, M. W. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_94-1 · Cited by 4
Disorders due to Substance Use: Hallucinogens and MDMA-Related Substances
Nayak, S. M., & Johnson, M. W. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_94 · Cited by 2
Coelho, S. G., Kim, H. S. A., Keough, M. T., Dawson, S. J., Tabri, N., Hodgins, D. C., Shead, N. W., & Wardell, J. D. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01381-2 · Cited by 5
“Given heterogeneity across research on the relative therapeutic benefits and risks of hallucinogen use (De Gregorio et al., 2021; Halpern et al., 2018; Johnson et al., 2018; Skryabin et al., 2018; Thomas & Malcolm, 2021), our findings suggest a need for targeted hallucinogen education efforts for…”
Perceived Availability of Lysergic Acid Diethylamide in the United States from 2015 to 2019
Barnett, B. S., Anand, A., Dewey, E. N., Hoffer, L., & Weleff, J. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0045 · Cited by 2
“9 These potential harms underscore the importance of monitoring trends in perceived availability of LSD (paLSD) as a means of anticipating shifts in use and informing harm reduction strategies.”
The psychedelic renaissance: psilocybin, a breakthrough for treatment resistant depression?
Norman, T. R. (2025) · Exploration of neuroscience · doi:10.37349/en.2025.1006105 · Cited by 2
Hallucinogen-Related Disorders
Kim, K. K., & Roberts, D. E. (2021) · Psychiatry update · doi:10.1007/978-3-030-86430-9_5 · Cited by 4
Husain, M. I., Umer, M., & Mulsant, B. H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2063274 · Cited by 2
Visual hallucinations and lifetime use of HPPD-related drugs: Results from a large online survey
Linszen, M. M. J., Kleijer, H., & Sommer, I. E. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.11.224 · Cited by 1
Metadata
- Authors
- Halpern, J. H., Lerner, A. G., & Passie, T.
- Affiliations
- Harvard University (US)
- Tel Aviv University (IL)
- Goethe University Frankfurt (DE)
- Corresponding author
- Halpern, John H.
- Venue
- Current Topics in Behavioral Neurosciences
- Publisher
- Springer Berlin Heidelberg
- Published
- 2016
- Volume
- 36
- Pages
- 333-360
- ISSN
- 1866-3370 (ISSN-L)
- 1866-3389
- OpenAlex
- W2552761136
- Cited by
- 133
- References
- 55
- Citations by year
- 2026: 8 · 2025: 19 · 2024: 25 · 2023: 17 · 2022: 23 · 2021: 16 · 2020: 12 · 2019: 4 · 2018: 5 · 2017: 4
- FWCI
- 26.44
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Current topics in behavioral neurosciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- hallucinogen persisting perception disorder, perceptual distortion, dissociative symptoms, anxiety, tinnitus, psychiatric comorbidity
- MeSH terms
- Adolescent, Adult, Chronic Disease, Female, Hallucinations, Hallucinogens, Humans, Male, Perceptual Disorders, Surveys and Questionnaires, Risk Factors, Prevalence, Diagnostic and Statistical Manual of Mental Disorders, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.